Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 314, 50-57
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Nationaal MS Fonds Nederland
This publication has 42 references indexed in Scilit:
- Reference genes in real-time PCRJournal of Applied Genetics, 2013
- A randomised, double blind, placebo controlled trial with vitamin D3as an add on treatment to interferon β-1b in patients with multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Soluble IL-2Rα facilitates IL-2–mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphomaBlood, 2011
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Vitamin D Status Is Positively Correlated with Regulatory T Cell Function in Patients with Multiple SclerosisPLOS ONE, 2009
- Compromised CD4+ CD25high regulatory T‐cell function in patients with relapsing‐remitting multiple sclerosis is correlated with a reduced frequency of FOXP3‐positive cells and reduced FOXP3 expression at the single‐cell levelImmunology, 2007
- Serum 25-Hydroxyvitamin D Levels and Risk of Multiple SclerosisJAMA, 2006
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsJournal of Experimental Medicine, 2006
- Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cellsJournal of Experimental Medicine, 2006
- 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells.Journal of Clinical Investigation, 1984